We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
GB Sciences Inc (PK) | USOTC:GBLX | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00043 | 6.85% | 0.00671 | 0.005 | 0.0068 | 0.0068 | 0.005 | 0.005 | 81,311 | 21:00:06 |
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 Or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 12, 2019
GB Sciences, Inc.
(Exact name of Registrant as specified in its charter)
Nevada
(State or other Jurisdiction of
|
000-55462 (Commission File Number) |
59-3733133 (IRS Employer I.D. No.) |
3550 W. Teco Avenue
Las Vegas, Nevada 89118
Phone: (844) 843-2569
(Address, including zip code, and telephone number, including area code, of
registrant’s principal executive offices)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule l 4a- l 2 under the Exchange Act ( 17 CFR 240. l 4a- l 2)
☐ Pre-commencement communications pursuant to Rule l 4d-2(b) under the Exchange Act (17 CFR 240. l 4d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240. l 3e-4(c))
Item 8.01 Other Events.
On September 12, 2019, the Registrant, GB Sciences, Inc. (the “Company”), and K2 Logic, LLC (“K2”) signed a term sheet pursuant to which K2 will pursue the purchase of the Company’s 50% ownership interest in GB Science Louisiana, LLC in exchange for $8,000,000 in cash. The Company may also receive up to an additional $8,000,000 over time through certain earn out provisions. The parties will negotiate and draft a Purchase and Sale Agreement with the intent to close the transaction by October 31, 2019.
1
SIGNATURE PAGE
Pursuant to the requirement of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
GB Sciences, Inc. |
|
||
|
|
|
|
|
Dated: September 13, 2019 |
|
By: |
/s/ John Poss |
|
|
|
|
John Poss |
|
|
|
|
Chief Executive Officer |
|
2
1 Year GB Sciences (PK) Chart |
1 Month GB Sciences (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions